Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects

• Published in: Critical reviews in oncology/hematology Vol. 190; p. 104085
• Main Authors: Raghani, Neha R., Shah, Disha D., Shah, Tithi S., Chorawala, Mehul R., Patel, Rakesh B.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2023
• Subjects: BTK inhibitors; CAR-T cell therapy; CDK inhibitors; Immunotherapy; Mantle cell lymphoma; Non-Hodgkin’s lymphoma; Non-Hodgkin’s lymphoma; CDK inhibitors; BTK inhibitors; Immunotherapy; CAR-T cell therapy; Mantle cell lymphoma
• ISSN: 1040-8428; 1879-0461; 1879-0461
• DOI: 10.1016/j.critrevonc.2023.104085

Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin’s lymphoma (NHL), accounting for 5% of all cases. Due to its virulence factor, it is an incurable disease and keeps relapsing despite an intensive treatment regimen. Advancements in research and drug discovery have shifted the treatment strategy from conventional chemotherapy to targeted agents and immunotherapies. The establishment of the role of Bruton tyrosine kinase led to the development of ibrutinib, a first-generation BTK inhibitor, and its successors. A conditioning regimen based immunotherapeutic agent like ibritumumob, has also demonstrated a viable response with a favorable toxicity profile. Brexucabtagene Autoleucel, the only approved CAR T-cell therapy, has proven advantageous for relapsed/refractory MCL in both children and adults. This article reviews certain therapies that could help update the current approach and summarizes a few miscellaneous agents, which, seldom studied in trials, could alleviate the regression observed in traditional therapies. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. [Display omitted] •Herein, we aim to outline the advancements in the therapeutic strategies for relapsed/refractory Mantle cell lymphoma (r/r-MCL).•The promising role of Bruton tyrosine inhibitors and CAR T-cell therapy in r/r-MCL have been discussed.•Various immunotherapeutic agents have also been elucidated which hold a significant position for management of r/r-MCL.•This review offers a comprehensive insight into advancing novel molecules for r/r-MCL and thereby enhancing patient outcomes.